Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Next Previous
Trial Profile

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms SU2C-SARC032

Most Recent Events

  • 04 Jun 2024 Results (n=143) evaluating the safety and efficacy of adding pembro to standard of care (SOC) RT & surgery for pts with stage III UPS or LPS were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 03 Jun 2024 According to a Stand Up To Cancer media release, over the course of six years - beginning in 2017 - the researchers persevered to enroll enough patients, even as the COVID-19 pandemic slowed work considerably for many months. During that time, SU2C worked closely with the team to extend funding timelines and support the completion of the trial.
  • 03 Jun 2024 According to a Stand Up To Cancer media release, result from this trial was presented today at the 2024 American Society of Clinical Oncology Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top